Immatics (NASDAQ:IMTX) Earns “Overweight” Rating from Cantor Fitzgerald

Immatics (NASDAQ:IMTX)‘s stock had its “overweight” rating reaffirmed by stock analysts at Cantor Fitzgerald in a report released on Tuesday,Benzinga reports.

Immatics Stock Down 4.9 %

Shares of IMTX stock traded down $0.22 during mid-day trading on Tuesday, reaching $4.29. 381,142 shares of the company’s stock traded hands, compared to its average volume of 626,234. Immatics has a 12 month low of $4.06 and a 12 month high of $13.77. The company’s 50-day moving average price is $4.94 and its 200-day moving average price is $7.37. The company has a market cap of $511.92 million, a P/E ratio of -6.42 and a beta of 0.83.

Immatics (NASDAQ:IMTX) last announced its quarterly earnings results on Thursday, March 27th. The company reported $0.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.51. The company had revenue of $15.67 million for the quarter, compared to analysts’ expectations of $16.16 million. Immatics had a negative net margin of 47.94% and a negative return on equity of 15.90%. Equities analysts predict that Immatics will post -0.72 earnings per share for the current year.

Institutional Trading of Immatics

A number of large investors have recently made changes to their positions in the stock. Bank of America Corp DE increased its position in Immatics by 166.0% during the fourth quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock valued at $25,000 after acquiring an additional 2,231 shares during the last quarter. Virtus ETF Advisers LLC raised its position in shares of Immatics by 34.8% during the 4th quarter. Virtus ETF Advisers LLC now owns 9,594 shares of the company’s stock valued at $68,000 after purchasing an additional 2,479 shares during the period. Texas Capital Bank Wealth Management Services Inc purchased a new position in shares of Immatics in the third quarter valued at about $114,000. Quarry LP raised its position in shares of Immatics by 29.4% during the third quarter. Quarry LP now owns 11,000 shares of the company’s stock valued at $126,000 after buying an additional 2,500 shares during the last quarter. Finally, Guggenheim Capital LLC bought a new position in shares of Immatics during the 4th quarter valued at about $101,000. 64.41% of the stock is currently owned by institutional investors.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.